These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 15952912)

  • 1. New therapeutic agents for the treatment of bone diseases.
    Lipton A
    Expert Opin Biol Ther; 2005 Jun; 5(6):817-32. PubMed ID: 15952912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K; Plosker GL
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
    Harvey HA
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):23-30. PubMed ID: 15719598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
    Gralow J
    Clin Breast Cancer; 2005 Feb; 5 Suppl(2):S54-62. PubMed ID: 15807925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.
    Rosen L; Harland SJ; Oosterlinck W
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S19-24. PubMed ID: 12562047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid: past, present and future roles in cancer treatment.
    Saad F
    Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
    Coukell AJ; Markham A
    Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid in the management of metastatic bone disease.
    Santini D; Fratto ME; Vincenzi B; Galluzzo S; Tonini G
    Expert Opin Biol Ther; 2006 Dec; 6(12):1333-48. PubMed ID: 17223741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
    Coleman RE
    Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
    Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
    Sakurai T
    Clin Calcium; 2007 Jan; 17(1):24-8. PubMed ID: 17211090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid: multiplicity of use across the cancer continuum.
    Lipton A
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid: a review of its use in breast cancer.
    Lyseng-Williamson KA
    Drugs; 2008; 68(18):2661-82. PubMed ID: 19093706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Zoledronic acid and bone pathology in the course of neoplasia. Part I].
    Caffo O
    Tumori; 2005; 91(5):22-6. PubMed ID: 16459649
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antitumor activity of zoledronic acid].
    Tamási L
    Magy Onkol; 2009 Sep; 53(3):269-71. PubMed ID: 19793692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
    Smith MR
    Cancer Treat Rev; 2005; 31 Suppl 3():19-25. PubMed ID: 16229955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.